The US Centers for Medicare and Medicaid Services on 12 January approved a final reimbursement regulation, the Medicare Coverage of Innovative Technology rule, which the medtech industry has been pushing the agency to adopt for the last several years. However, there is a worry the new rule – a product of the Trump administration – could be temporarily or permanently blocked by the incoming Biden administration.
Under the MCIT regulation, as soon as the Food and Drug Administration approves a new breakthrough device or diagnostic, Medicare will cover it.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?